Ute I. Scholl

Ute I. Scholl

Auto-generated profile, based on publicly available information

Ute I. Scholl

Center of Genomic Medicine, Berlin Institute of Health at Charité — Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
HSHolger Scholz
Holger Scholz
FBFelix J. Boivin
Felix J. Boivin
KSKai M. Schmidt-Ott
Kai M. Schmidt-Ott
SBSebastian Bachmann
Sebastian Bachmann
KEKai-Uwe Eckardt
Kai-Uwe Eckardt
PPPontus B. Persson
Pontus B. Persson

5 February 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
USUte I. Scholl
Ute I. Scholl
GSGabriel Stölting
Gabriel Stölting
JSJulia Schewe
Julia Schewe
ATAnne Thiel
Anne Thiel
HTHua Tan
Hua Tan
RLRichard P. Lifton
Richard P. Lifton

12 August 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
HHHenrike O. Heyne
Henrike O. Heyne
DBDavid Baez-Nieto
David Baez-Nieto
SISumaiya Iqbal
Sumaiya Iqbal
DPDuncan S. Palmer
Duncan S. Palmer
ABAndreas Brunklaus
Andreas Brunklaus
MDMark J. Daly
Mark J. Daly
A machine learning method can predict loss- versus gain-of-function effects of human genetic variants in disease-associated ion channels.

7 August 2015 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
USUte I. Scholl
Ute I. Scholl
JHJames Healy
James Healy
ATAnne Thiel
Anne Thiel
AFAnnabelle L. Fonseca
Annabelle L. Fonseca
TBTaylor C. Brown
Taylor C. Brown
TCTobias Carling
Tobias Carling

1 May 2022 in Hypertension
Verified
Journal Article
Open access
PDF file
USUte I. Scholl
Ute I. Scholl
Primary aldosteronism is considered the commonest cause of secondary hypertension. In affected individuals, aldosterone is produced in an at least partially autonomous fashion in adrenal lesions (adenomas, [micro]nodules or diffuse hyperplasia). Over the past decade, next-generation sequencing studies have led to the insight that primary aldosteronism is largely a genetic disorder. Sporadic cases are due to somatic mutations, mostly in ion channels and pumps, and rare cases of familial hyperaldosteronism are caused by germline mutations in an overlapping set of genes. More than 90% of aldosterone-producing adenomas carry somatic mutations in K + channel Kir3.4 ( KCNJ5 ), Ca 2+ channel Ca V 1.3 ( CACNA1D ), alpha-1 subunit of the Na + /K + ATPase ( ATP1A1 ), plasma membrane Ca 2+ transporting ATPase 3 ( ATP2B3 ), Ca 2+ channel Ca V 3.2 ( CACNA1H ), Cl − channel ClC-2 ( CLCN2 ), β-catenin ( CTNNB1 ), and/or G-protein subunits alpha q/11 ( GNAQ/11 ). Mutations in some of these genes have also been identified in aldosterone-producing (micro)nodules, suggesting a disease continuum from a single cell, acquiring a somatic mutation, via a nodule to adenoma formation, and from a healthy state to subclinical to overt primary aldosteronism. Individual glands can have multiple such lesions, and they can occur on both glands in bilateral disease. Familial hyperaldosteronism, typically with early onset, is caused by germline mutations in steroid 11-beta hydroxylase/ aldosterone synthase ( CYP11B1/2 ), CLCN2 , KCNJ5 , CACNA1H , and CACNA1D .

12 June 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
USUte I. Scholl
Ute I. Scholl
LALaura Abriola
Laura Abriola
CZChengbiao Zhang
Chengbiao Zhang
EREsther N. Reimer
Esther N. Reimer
MPMark Plummer
Mark Plummer
RLRichard P. Lifton
Richard P. Lifton
Aldosterone-producing adenomas (APAs) are benign tumors of the adrenal gland that constitutively produce the salt-retaining steroid hormone aldosterone and cause millions of cases of severe hypertension worldwide. Either of 2 somatic mutations in the potassium channel KCNJ5 (G151R and L168R, hereafter referred to as KCNJ5MUT) in adrenocortical cells account for half of APAs worldwide. These mutations alter channel selectivity to allow abnormal Na+ conductance, resulting in membrane depolarization, calcium influx, aldosterone production, and cell proliferation. Because APA diagnosis requires a difficult invasive procedure, patients often remain undiagnosed and inadequately treated. Inhibitors of KCNJ5MUT could allow noninvasive diagnosis and therapy of APAs carrying KCNJ5 mutations. Here, we developed a high-throughput screen for rescue of KCNJ5MUT-induced lethality and identified a series of macrolide antibiotics, including roxithromycin, that potently inhibit KCNJ5MUT, but not KCNJ5WT. Electrophysiology demonstrated direct KCNJ5MUT inhibition. In human aldosterone-producing adrenocortical cancer cell lines, roxithromycin inhibited KCNJ5MUT-induced induction of CYP11B2 (encoding aldosterone synthase) expression and aldosterone production. Further exploration of macrolides showed that KCNJ5MUT was similarly selectively inhibited by idremcinal, a macrolide motilin receptor agonist, and by synthesized macrolide derivatives lacking antibiotic or motilide activity. Macrolide-derived selective KCNJ5MUT inhibitors thus have the potential to advance the diagnosis and treatment of APAs harboring KCNJ5MUT.